Dexamethaxone Sodium Phosphate (Decadron)

Category:

  • Miscellaneous

Description:

  • Adrenal corticosteroid

Indications:

  • Anti-inflammatory or immunosuppressant agent in the treatment of  a variety of diseases including those of hematologic, allergic, inflammatory, neoplastic, and autoimmune origin

Contraindications:

  • Systemic fungal infections

  • Hypersensitivity to any component of the product, including sulfites.  Dexamethasone sodium phosphate contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people.

Precautions:

  • Pregnancy category C: Newborns may exhibit signs of adrenal insufficiency; excreted in breast milk and may suppress growth and cause other unwanted effects

  • Psychotic derangements may appear

  • Following prolonged therapy, withdrawal symptoms may include fever, myalgia, arthralgia, and malaise

  • Use lowest possible dose

Adverse Reactions (Side Effects):

  • METAB: sodium retention, fluid retention, CHF, potassium loss, hypokalemic acidosis, hypertension, negative nitrogen balance

  • MS: muscle weakness, osteoporosis, steroid myopathy, tendon rupture, pathological fracture of long bones, vertebral compression fractures

  • GI: peptic ulcer, pancreatitis, abdominal distention, ulcerative esophagitis

  • SKIN: erythema, increased sweating, petechiae and ecchymoses, urticaria

  • ENDO: cushionoid state, supressed growth, menstrual irregularities, hirsutism, secondary adrenocortical and pituitary unresponsiveness

  • NEURO: convulsions, vertigo, headache, psychic disturbances, increased intracranial pressure with papilledema

  • OTHER: weight gain, increased appetite, thromboemolism, hiccups, nausea, malaise  

Dosage:

For intravenous, intramuscular, intraarticular, intralesional, and soft tissue injection

Dexamethasone sodium phosphate injection can be given directly from the vial, or it can be added to Sodium Chloride Injection or Dextrose Injection and adminsitered by intravenous drip.

  • Adult:   

    • Shock: 

      • IV 1-6 mg/kg or 40mg every 2-6 hours

    • Prophylaxis during premature labor: (to prevent infant respiratory distress due to immature lungs)

      •  6mg every 12 hours for 4 doses

    • Intra-articular and soft tissue: 

      • large joints 2-4mg

      • small joints 0.8-1mg

      • bursae 2-3mg

      • tendon sheaths 0.4-1mg, soft tissue infiltration 2-6mg

      • ganglia 1-2mg

Dosage requirements are variable and must be individualized on the basis of the disease and the response of the patient.

Persons on immunosuppressant doses should avoid exposure to chickenpox or measles; if exposed, they should seek medical advice without delay

 

Home  ·  Military Medicine  ·  Sick Call  ·  Basic Exams  ·  Medical Procedures  ·  Lab and X-ray  ·  The Pharmacy  ·  The Library  ·  Equipment  ·  Patient Transport  ·  Medical Force Protection  ·  Operational Safety  ·  Operational Settings  ·  Special Operations  ·  Humanitarian Missions  ·  Instructions/Orders  ·  Other Agencies  ·  Video Gallery  ·  Forms  ·  Web Links  ·  Acknowledgements  ·  Help  ·  Feedback

Approved for public release; Distribution is unlimited.

The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks.

Source: Operational Medicine 2001, Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300.

Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300

Operational Medicine
 Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
  January 1, 2001

United States Special Operations Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323

*This web version is provided by The Brookside Associates, LLC.  It contains original contents from the official US Navy NAVMED P-5139, but has been reformatted for web access and includes advertising and links that were not present in the original version. The medical information presented was reviewed and felt to be accurate in 2001. Medical knowledge and practice methods may have changed since that time. Some links may no longer be active. This web version has not been approved by the Department of the Navy or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. The Brookside Associates is a private organization, not affiliated with the United States Department of Defense.

© 2015, Brookside Associates, LLC. All rights reserved

Other Brookside Products

 

 

Advertise on this site